Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.

Published Date: 10 Apr 2024

Patients with surgically removed HPV-negative head and neck squamous cell cancer (HNSCC) experienced low rates of disease relapse after receiving the personalized neoantigen vaccine TG4050, which stimulated tumor-specific immune responses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Converging' Evidence of Link Between Air Pollution and Breast Cancer

2.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

3.

Prostate cancer Q&A: Improving detection and reducing overtreatment

4.

New opportunities for screening and treatment have been created by the identification of the genetic drivers of esophageal cancer.

5.

Cancer patients want financial screening early in care, study finds


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot